TEST FEATURES
This panel includes 513 genes for DNA analysis and 49 genes for RNA (fusion) detection. It identifies cancer signatures by analyzing key parameters such as SNV, CNV, TMB, MSI, and HRD. One of its key advantages is that it requires a minimal sample amount of just 10 ng, with a sensitivity of over 99.5% and a specificity greater than 97.6%.
- Single gene biomarkers
Detects single nucleotide variants (SNV), insertions and deletions, known and novel fusions, copy number variants (CNV).
- Multigene biomarkers
Determines susceptibility to mutations with tumor mutation burden (TMB) and microsatellite instability (MSI)scoring and allows analyzing mutation signatures and potential responses to immunotherapies.
- Simultaneous analysis of 49 fusion genes
Enables direct detection of 1311 known fusion isoforms and new unknown fusion isoforms.
- Homologous recombination repair deficiency (HRD)
Detects loss of heterozygosity (LOH) at both gene and sample level to identify genomic instability in 46 key genes involved in homologous recombination repair pathways.
- Ability to work with low amounts of samples
10 ng or more DNA/RNA sample isolated from tissue is sufficient for analysis. Thus, it makes it possible to perform with more analysis options with smaller amounts of tissue compared to conventional tests.
- High test success
- Increased success in results thanks to high sequencing success rates (up to 95% ), allowing more samples to be tested without any problems.
- Highly automated workflow
- Automated and short run protocol helps increase laboratory efficiency and reduce potential user errors.
Benefits
- Targeted therapy
- Personalized treatment
- Smart drug / immunotherapy
- Possibility of avoiding the potential side effects of chemotherapy
For more information download the PDF brochure.